{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:03:38Z","timestamp":1793325818985,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s11906-019-0924-0","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T09:03:18Z","timestamp":1551517398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and\/or Cost or Just a Men\u2019s Issue?"],"prefix":"10.1007","volume":"21","author":[{"given":"Antonis A.","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora A.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Melita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis S.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,2]]},"reference":[{"issue":"1","key":"924_CR1","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"\u2022 Kolkhof P, Barfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u2013t40. An important review of the history of the various generations of MRAs.","journal-title":"J Endocrinol"},{"issue":"5","key":"924_CR2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2215\/CJN.01060306","volume":"1","author":"DA Calhoun","year":"2006","unstructured":"Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006;1(5):1039\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1\u20132","key":"924_CR3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217(1\u20132):27\u201331.","journal-title":"Mol Cell Endocrinol"},{"key":"924_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/VHRM.S138599","volume":"13","author":"JC Yugar-Toledo","year":"2017","unstructured":"Yugar-Toledo JC, Modolo R, de Faria AP, Moreno H. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists. Vasc Health Risk Manag. 2017;13:403\u201311.","journal-title":"Vasc Health Risk Manag"},{"issue":"7","key":"924_CR5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","volume":"129","author":"M Epstein","year":"2016","unstructured":"Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016. Am J Med. 2016;129(7):661\u20136.","journal-title":"Am J Med"},{"issue":"10008","key":"924_CR6","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"\u2022\u2022 Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368. A pivotal trial establishing the role of spironolactone in the treatment of resistant hypertension.","journal-title":"Lancet"},{"issue":"4","key":"924_CR7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","volume":"71","author":"EM Krieger","year":"2018","unstructured":"\u2022 Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment). Hypertension. 2018;71(4):681\u201390. An important trial suggesting spironolactone as the preferable fourth agent for resistant hypertension.","journal-title":"Hypertension"},{"issue":"10","key":"924_CR8","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/HJH.0b013e3282a9be30","volume":"25","author":"E Pimenta","year":"2007","unstructured":"\u2022 Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, et al. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens. 2007;25(10):2131\u20137. Important prospective study suggesting a role of aldosterone excess in resistant hypertension.","journal-title":"J Hypertens"},{"issue":"11","key":"924_CR9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"\u2022 Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159\u201364. An important prospective study suggesting a role of intravascular volume expansion in resistane hypertension.","journal-title":"Arch Intern Med"},{"issue":"9","key":"924_CR10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/jhh.2010.95","volume":"25","author":"LC Martins","year":"2011","unstructured":"Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011;25(9):532\u20138.","journal-title":"J Hum Hypertens"},{"issue":"2","key":"924_CR11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40(2):117\u201323.","journal-title":"Hypertension"},{"issue":"6","key":"924_CR12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","volume":"2","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2(6):462\u20138.","journal-title":"J Am Soc Hypertens"},{"issue":"11","key":"924_CR13","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","volume":"28","author":"K Dahal","year":"2015","unstructured":"\u2022 Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28(11):1376\u201385. A meta-analysis showing that MRAs are safe and effective therapy in patients with resistant hypertension.","journal-title":"Am J Hypertens"},{"issue":"5","key":"924_CR14","first-page":"7270","volume":"8","author":"H Guo","year":"2015","unstructured":"\u2022 Guo H, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta analysis from randomized controlled clinical trials. Int J Clin Exp Med. 2015;8(5):7270\u20138. A meta-analysis on the efficacy of spironolactone in resistant hypertension.","journal-title":"Int J Clin Exp Med"},{"issue":"3","key":"924_CR15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10641963.2016.1246564","volume":"39","author":"L Liu","year":"2017","unstructured":"\u2022 Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a meta-analysis of randomized controlled trials. Clin Exp Hypertens. 2017;39(3):257\u201363. A meta-analysis on the benefit of spironolactone in patients with resistant hypertension.","journal-title":"Clin Exp Hypertens"},{"issue":"3","key":"924_CR16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cjca.2012.03.010","volume":"28","author":"D Clark 3rd","year":"2012","unstructured":"Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28(3):318\u201325.","journal-title":"Can J Cardiol"},{"issue":"12","key":"924_CR17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/jhh.2017.70","volume":"31","author":"WD Zhang","year":"2017","unstructured":"Zhang WD, Zhang JW, Wu KF, Chen X, Wang YP, Zhou LH, et al. Effect of aldosterone antagonists on obstructive sleep apnea in patients with resistant hypertension: a systematic review and meta-analysis. J Hum Hypertens. 2017;31(12):855\u20136.","journal-title":"J Hum Hypertens"},{"issue":"5","key":"924_CR18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","volume":"6","author":"M Briet","year":"2010","unstructured":"Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6(5):261\u201373.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"924_CR19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MNH.0b013e32834fb25b","volume":"21","author":"A Nguyen Dinh Cat","year":"2012","unstructured":"Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens. 2012;21(2):147\u201356.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"924_CR20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11906-006-0059-y","volume":"8","author":"SM Mackenzie","year":"2006","unstructured":"Mackenzie SM, Connell J. Hypertension and the expanding role of aldosterone. Curr Hypertens Rep. 2006;8(3):255\u201361.","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"924_CR21","doi-asserted-by":"crossref","first-page":"17a","DOI":"10.1016\/0002-9149(93)90240-D","volume":"71","author":"DA Duprez","year":"1993","unstructured":"Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1993;71(3):17a\u201320a.","journal-title":"Am J Cardiol"},{"key":"924_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","volume":"970","author":"R Rocha","year":"2002","unstructured":"Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89\u2013100.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"924_CR23","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63(5):1791\u2013800.","journal-title":"Kidney Int"},{"issue":"1","key":"924_CR24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjhyper.2005.05.013","volume":"19","author":"K Matsumura","year":"2006","unstructured":"Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006;19(1):13\u20138.","journal-title":"Am J Hypertens"},{"issue":"2","key":"924_CR25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijcard.2011.06.100","volume":"164","author":"T Dartsch","year":"2013","unstructured":"Dartsch T, Fischer R, Gapelyuk A, Weiergraeber M, Ladage D, Schneider T, et al. Aldosterone induces electrical remodeling independent of hypertension. Int J Cardiol. 2013;164(2):170\u20138.","journal-title":"Int J Cardiol"},{"issue":"4","key":"924_CR26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1515\/jpem.2010.052","volume":"23","author":"A Martinez-Aguayo","year":"2010","unstructured":"Martinez-Aguayo A, Carvajal CA, Campino C, Aglony M, Bolte L, Garcia H, et al. Primary aldosteronism and its impact on the generation of arterial hypertension, endothelial injury and oxidative stress. J Pediatr Endocrinol Metab. 2010;23(4):323\u201330.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"924_CR27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.HYP.0000201443.63240.a7","volume":"47","author":"EL Schiffrin","year":"2006","unstructured":"Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312\u20138.","journal-title":"Hypertension"},{"issue":"2","key":"924_CR28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/01.HYP.0000083298.23119.16","volume":"42","author":"BM Schmidt","year":"2003","unstructured":"Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension. 2003;42(2):156\u201360.","journal-title":"Hypertension"},{"issue":"23","key":"924_CR29","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","volume":"109","author":"MK Nishizaka","year":"2004","unstructured":"Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109(23):2857\u201361.","journal-title":"Circulation"},{"issue":"1","key":"924_CR30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt197925133","volume":"25","author":"G Schrijver","year":"1979","unstructured":"Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther. 1979;25(1):33\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"924_CR31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5694\/j.1326-5377.1980.tb134686.x","volume":"1","author":"A Ludbrook","year":"1980","unstructured":"Ludbrook A, Dynon M, Mendelsohn FA, Louis WJ. Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension. Med J Aust. 1980;1(3):124\u20135.","journal-title":"Med J Aust"},{"issue":"1","key":"924_CR32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F Souza de","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55(1):147\u201352.","journal-title":"Hypertension"},{"issue":"11 Pt 1","key":"924_CR33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925\u201330.","journal-title":"Am J Hypertens"},{"issue":"4","key":"924_CR34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839\u201345.","journal-title":"Hypertension"},{"key":"924_CR35","first-page":"Cd008169","volume":"8","author":"J Batterink","year":"2010","unstructured":"\u2022 Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev. 2010;8:Cd008169. A meta-analysis on the role of spironolactone in the treatment of hypertension pointing to reasonable dosing of 25\u2013100\u00a0mg\/day.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"924_CR36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15(8):709\u201316.","journal-title":"Am J Hypertens"},{"issue":"5","key":"924_CR37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41(5):1021\u20136.","journal-title":"Hypertension"},{"issue":"15","key":"924_CR38","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"\u2022 Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831\u20138. An important study demonstrating the efficacy of eplerenone in LVH regression and blood pressure control.","journal-title":"Circulation"},{"issue":"1","key":"924_CR39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","volume":"92","author":"WB White","year":"2003","unstructured":"White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003;92(1):38\u201342.","journal-title":"Am J Cardiol"},{"issue":"7","key":"924_CR40","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41(7):1148\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"924_CR41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijcard.2014.09.091","volume":"177","author":"F Pelliccia","year":"2014","unstructured":"\u2022 Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int J Cardiol. 2014;177(1):219\u201328. A meta-analysis demonstrating the efficacy and safety of eplerenone in treating hypertension.","journal-title":"Int J Cardiol"},{"key":"924_CR42","first-page":"Cd008996","volume":"2","author":"TS Tam","year":"2017","unstructured":"\u2022 Tam TS, Wu MH, Masson SC, Tsang MP, Stabler SN, Kinkade A, et al. Eplerenone for hypertension. Cochrane Database Syst Rev. 2017;2:Cd008996. A meta-analysis on the role of eplerenone in the treatment of hypertension pointing to effective dosing of 50\u00a0mg\/day.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"924_CR43","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(12):944\u201353.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"924_CR44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"\u2022\u2022 Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98\u2013105. A meta-analysis of a large pooled sample of hypertensive patients indicating high global prevalence of resistant hypertension.","journal-title":"Heart"},{"issue":"12","key":"924_CR45","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/hr.2013.92","volume":"36","author":"AP Faria de","year":"2013","unstructured":"de Faria AP, Demacq C, Figueiredo VN, Moraes CH, Santos RC, Sabbatini AR, et al. Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res. 2013;36(12):1067\u201372.","journal-title":"Hypertens Res"},{"issue":"5","key":"924_CR46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1751-7176.2009.00110.x","volume":"11","author":"S Ubaid-Girioli","year":"2009","unstructured":"Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR, et al. Aldosterone excess or escape: treating resistant hypertension. J Clin Hypertens (Greenwich). 2009;11(5):245\u201352.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"924_CR47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J Vaclavik","year":"2011","unstructured":"Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069\u201375.","journal-title":"Hypertension"},{"issue":"10","key":"924_CR48","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","volume":"31","author":"CS Oxlund","year":"2013","unstructured":"Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31(10):2094\u2013102.","journal-title":"J Hypertens"},{"issue":"6","key":"924_CR49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","volume":"4","author":"M Engbaek","year":"2010","unstructured":"Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens. 2010;4(6):290\u20134.","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"924_CR50","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"\u2022 Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464\u201375. An analysis of the PATHWAY-2 substudies indicating that resistant hypertension is a salt-retaining state due to inappropriate aldosterone secretion.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"924_CR51","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.hlc.2016.02.016","volume":"25","author":"C Wang","year":"2016","unstructured":"\u2022 Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25(10):1021\u201330. A meta-analysis on the efficacy and safety of spironolactone in resistant hypertension.","journal-title":"Heart Lung Circ"},{"issue":"3","key":"924_CR52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2047487316675194","volume":"24","author":"SJ Sinnott","year":"2017","unstructured":"\u2022 Sinnott SJ, Tomlinson LA, Root AA, Mathur R, Mansfield KE, Smeeth L, et al. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(3):228\u201338. A meta-analysis on the comparative effectiveness of MRAs in resistant hypertension.","journal-title":"Eur J Prev Cardiol"},{"key":"924_CR53","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","volume":"233","author":"D Zhao","year":"2017","unstructured":"Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol. 2017;233:113\u20137.","journal-title":"Int J Cardiol"},{"issue":"5","key":"924_CR54","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"\u2022 Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980\u201390. An important comparative RCT of spironolactone vs eplerenone.","journal-title":"J Hypertens"},{"issue":"3","key":"924_CR55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","volume":"150","author":"MH Weinberger","year":"2005","unstructured":"Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J. 2005;150(3):426\u201333.","journal-title":"Am Heart J"},{"issue":"4","key":"924_CR56","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","volume":"27","author":"PM Jansen","year":"2009","unstructured":"Jansen PM, Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27(4):680\u201391.","journal-title":"J Hypertens"},{"issue":"14","key":"924_CR57","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"\u2022\u2022 Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321. A pivotal trial of eplerenone in patients with left ventricular dysfunction after myocardial infarction.","journal-title":"N Engl J Med"},{"issue":"2","key":"924_CR58","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/HJH.0b013e32835b71d6","volume":"31","author":"PM Jansen","year":"2013","unstructured":"Jansen PM, Frenkel WJ, van den Born BJ, de Bruijne EL, Deinum J, Kerstens MN, et al. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension. J Hypertens. 2013;31(2):404\u201313.","journal-title":"J Hypertens"},{"issue":"2","key":"924_CR59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1515\/jtim-2017-0020","volume":"5","author":"JD Spence","year":"2017","unstructured":"Spence JD, Bogiatzi C, Kuk M, Dresser GK, Hackam DG. Effects of eplerenone on resistance to antihypertensive medication in patients with primary or secondary hyperaldosteronism. J Transl Int Med. 2017;5(2):93\u20139.","journal-title":"J Transl Int Med"},{"issue":"12","key":"924_CR60","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jch.12860","volume":"18","author":"K Eguchi","year":"2016","unstructured":"Eguchi K, Kabutoya T, Hoshide S, Ishikawa S, Kario K. Add-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertension. J Clin Hypertens (Greenwich). 2016;18(12):1250\u20137.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"924_CR61","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/HJH.0000000000001264","volume":"35","author":"A Schneider","year":"2017","unstructured":"Schneider A, Schwab J, Karg MV, Kalizki T, Reinold A, Schneider MP, et al. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension. J Hypertens. 2017;35(5):1086\u201392.","journal-title":"J Hypertens"},{"issue":"5","key":"924_CR62","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","volume":"55","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55(5):1137\u201342.","journal-title":"Hypertension"},{"issue":"2","key":"924_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00380-018-1250-1","volume":"34","author":"Masayoshi Yamamoto","year":"2018","unstructured":"\u2022 Yamamoto M, Seo Y, Ishizu T, Nishi I, Hamada-Harimura Y, Machino-Ohtsuka T, et al. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. Heart Vessels. 2018. \n                      https:\/\/doi.org\/10.1007\/s00380-018-1250-1\n                      \n                    . A comparative trial of spironolactone and eplerenone in patients with heart failure.","journal-title":"Heart and Vessels"},{"issue":"8","key":"924_CR64","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","volume":"125","author":"S Chatterjee","year":"2012","unstructured":"Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med. 2012;125(8):817\u201325.","journal-title":"Am J Med"},{"issue":"1","key":"924_CR65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","volume":"10","author":"DA Sica","year":"2005","unstructured":"Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10(1):23\u20139.","journal-title":"Heart Fail Rev"},{"key":"924_CR66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"issue":"10","key":"924_CR67","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","volume":"47","author":"JI Davies","year":"2004","unstructured":"Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004;47(10):1687\u201394.","journal-title":"Diabetologia"},{"key":"924_CR68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","volume":"188","author":"D Vukadinovic","year":"2017","unstructured":"\u2022\u2022 Vukadinovic D, Lavall D, Vukadinovic AN, Pitt B, Wagenpfeil S, Bohm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J. 2017;188:99\u2013108. A meta-analysis on MRA-related hyperkalemia but also raising the issue of non-MRA-related hyperkalemia.","journal-title":"Am Heart J"},{"issue":"12","key":"924_CR69","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4065\/80.12.1623","volume":"80","author":"WH Tang","year":"2005","unstructured":"Tang WH, Parameswaran AC, Maroo AP, Francis GS. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc. 2005;80(12):1623\u201330.","journal-title":"Mayo Clin Proc"},{"issue":"48","key":"924_CR70","doi-asserted-by":"crossref","first-page":"e8719","DOI":"10.1097\/MD.0000000000008719","volume":"96","author":"S Korol","year":"2017","unstructured":"\u2022 Korol S, Mottet F, Perreault S, Baker WL, White M, de Denus S. A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis. Medicine (Baltimore). 2017;96(48):e8719. A meta-analysis on the impact of MRAs on glycemia.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"924_CR71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40256-014-0066-3","volume":"14","author":"Z Ademi","year":"2014","unstructured":"\u2022 Ademi Z, Pasupathi K, Krum H, Liew D. Cost effectiveness of eplerenone in patients with chronic heart failure. Am J Cardiovasc Drugs. 2014;14(3):209\u201316. A cost-effectiveness analysis of eplerenone in heart failure.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"21","key":"924_CR72","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/heartjnl-2014-305673","volume":"100","author":"D Lee","year":"2014","unstructured":"\u2022 Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, et al. Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart. 2014;100(21):1681\u20137. A cost-effectiveness analysis of eplerenone in the EMPHASIS-HF trial.","journal-title":"Heart"},{"issue":"5","key":"924_CR73","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"\u2022\u2022 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889\u2013916. Endocrine Society Guidelines on the management of primary aldosteronism.","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"924_CR74","doi-asserted-by":"crossref","first-page":"E773","DOI":"10.1503\/cmaj.161486","volume":"189","author":"GA Kline","year":"2017","unstructured":"Kline GA, Prebtani APH, Leung AA, Schiffrin EL. Primary aldosteronism: a common cause of resistant hypertension. CMAJ. 2017;189(22):E773\u2013e8.","journal-title":"CMAJ"},{"issue":"3","key":"924_CR75","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/hr.2015.129","volume":"39","author":"S Karashima","year":"2016","unstructured":"Karashima S, Yoneda T, Kometani M, Ohe M, Mori S, Sawamura T, et al. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res. 2016;39(3):133\u20137.","journal-title":"Hypertens Res"},{"issue":"4","key":"924_CR76","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2125.1981.tb01271.x","volume":"12","author":"GM Bell","year":"1981","unstructured":"Bell GM, Fananapazir L, Anderton JL. Comparison of single and divided daily dose spironolactone in the control of hypertension. Br J Clin Pharmacol. 1981;12(4):585\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"924_CR77","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","volume":"102","author":"I Sungaila","year":"1992","unstructured":"Sungaila I, Bartle WR, Walker SE, DeAngelis C, Uetrecht J, Pappas C, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology. 1992;102(5):1680\u20135.","journal-title":"Gastroenterology"},{"issue":"6","key":"924_CR78","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351(6):543\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"924_CR79","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08998280.2004.11927973","volume":"17","author":"J Craft","year":"2004","unstructured":"Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Bayl Univ Med Cent). 2004;17(2):217\u201320.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"7","key":"924_CR80","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0091270005275894","volume":"45","author":"WR Ravis","year":"2005","unstructured":"Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol. 2005;45(7):810\u201321.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"924_CR81","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"\u2022\u2022 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709\u201317. A landmark trial on the effect of spironolactone on morbidity and mortality in patients with heart failure.","journal-title":"N Engl J Med"},{"issue":"1","key":"924_CR82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"\u2022 Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321. A pivotal trial of eplerenone in heart failure patients.","journal-title":"N Engl J Med"},{"issue":"3","key":"924_CR83","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","volume":"46","author":"B Pitt","year":"2005","unstructured":"\u2022\u2022 Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425\u201331. A pivotal trial of eplerenone in heart failure patients after myocardial infarction.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"924_CR84","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004926","volume":"11","author":"JP Ferreira","year":"2018","unstructured":"Ferreira JP, Duarte K, McMurray JJV, Pitt B, van Veldhuisen DJ, Vincent J, et al. Data-driven approach to identify subgroups of heart failure with reduced ejection fraction patients with different prognoses and aldosterone antagonist response patterns. Circ Heart Fail. 2018;11(7):e004926.","journal-title":"Circ Heart Fail."},{"issue":"22","key":"924_CR85","first-page":"2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investig Circ. 2000;102(22):2700\u20136.","journal-title":"Rales Investig Circ"},{"issue":"11","key":"924_CR86","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1253\/circj.69.1394","volume":"69","author":"N Nishikawa","year":"2005","unstructured":"Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Umekawa S, et al. Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophy. Circ J. 2005;69(11):1394\u2013400.","journal-title":"Circ J"},{"issue":"10","key":"924_CR87","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/pace.13169","volume":"40","author":"M Kawasaki","year":"2017","unstructured":"Kawasaki M, Yamada T, Okuyama Y, Morita T, Furukawa Y, Tamaki S, et al. Eplerenone might affect atrial fibrosis in patients with hypertension. Pacing Clin Electrophysiol. 2017;40(10):1096\u2013102.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"924_CR88","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/HYPERTENSIONAHA.107.103267","volume":"51","author":"C Savoia","year":"2008","unstructured":"Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51(2):432\u20139.","journal-title":"Hypertension"},{"issue":"6","key":"924_CR89","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101(6):594\u20137.","journal-title":"Circulation"},{"issue":"7","key":"924_CR90","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/jch.12986","volume":"19","author":"T Kalizki","year":"2017","unstructured":"Kalizki T, Schmidt BMW, Raff U, Reinold A, Schwarz TK, Schneider MP, et al. Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. J Clin Hypertens. 2017;19(7):669\u201376.","journal-title":"J Clin Hypertens"},{"issue":"5","key":"924_CR91","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59(5):1069\u201378.","journal-title":"Hypertension"},{"issue":"5","key":"924_CR92","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940\u201351.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"924_CR93","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"AS Bomback","year":"2008","unstructured":"Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis. 2008;51(2):199\u2013211.","journal-title":"Am J Kidney Dis"},{"key":"924_CR94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijcard.2016.12.029","volume":"231","author":"J Neefs","year":"2017","unstructured":"\u2022 Neefs J, van den Berg NW, Limpens J, Berger WR, Boekholdt SM, Sanders P, et al. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017;231:155\u201361. A meta-analysis on the effects of MRAs on atrial fibrillation.","journal-title":"Int J Cardiol"},{"issue":"9","key":"924_CR95","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/clc.20762","volume":"33","author":"J Wei","year":"2010","unstructured":"\u2022 Wei J, Ni J, Huang D, Chen M, Yan S, Peng Y. The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin Cardiol. 2010;33(9):572\u20137. A meta-analysis on the effects of MRAs on ventricular arrhythmias.","journal-title":"Clin Cardiol"},{"issue":"22","key":"924_CR96","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/heartjnl-2018-312950","volume":"104","author":"F Beygui","year":"2018","unstructured":"\u2022 Beygui F, Van Belle E, Ecollan P, Machecourt J, Hamm CW, Lopez De Sa E, et al. Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. Heart. 2018;104(22):1843\u20139. An important analysis of data on the effect of MRAs on total and sudden death mortality after a myocardial infarction.","journal-title":"Heart"},{"issue":"17","key":"924_CR97","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"R Eschalier","year":"2013","unstructured":"\u2022 Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62(17):1585\u201393. A subgroup analysis of the EMPHASIS-HF trial on the effect of eplerenone in patients prone to hyperkalemia.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"924_CR98","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","volume":"30","author":"N Khosla","year":"2009","unstructured":"Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30(5):418\u201324.","journal-title":"Am J Nephrol"},{"issue":"3\u20134","key":"924_CR99","first-page":"381","volume":"128","author":"S Gwoo","year":"2014","unstructured":"Gwoo S, Kim YN, Shin HS, Jung YS, Rim H. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease. Nephron Clin Pract. 2014;128(3\u20134):381\u20136.","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"924_CR100","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","volume":"63","author":"Y Matsumoto","year":"2014","unstructured":"Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63(6):528\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"924_CR101","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820\u20138.","journal-title":"Eur Heart J"},{"issue":"16","key":"924_CR102","doi-asserted-by":"crossref","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","volume":"97","author":"H Pei","year":"2018","unstructured":"\u2022 Pei H, Wang W, Zhao D, Wang L, Su GH, Zhao Z. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(16):e0254. Data on the new MRA, finerenone.","journal-title":"Medicine (Baltimore)"},{"key":"924_CR103","unstructured":"\u2022\u2022 NICE. Hypertension in adults: diagnosis and management. 2016. \n                      https:\/\/www.nice.org.uk\/guidance\/cg127\n                      \n                    . British guidelines on hypertension. Accessed 29 Oct 2018"},{"issue":"19","key":"924_CR104","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"\u2022\u2022 Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248. New (2018) American guidelines on hypertension.","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"924_CR105","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"\u2022\u2022 Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. New (2018) European guidelines on hypertension.","journal-title":"Eur Heart J"},{"issue":"5","key":"924_CR106","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"\u2022\u2022 Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53\u201390. New (2018) scientific statement from the American Heart Association on resistant hypertension.","journal-title":"Hypertension"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-019-0924-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-019-0924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:25:21Z","timestamp":1583022321000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-019-0924-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s11906-019-0924-0","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"22"}}